Kim Han Byul, Hong Young Joon, Park Hyuk Jin, Ahn Youngkeun, Jeong Myung Ho
Division of Cardiology, Chonnam National University Hospital, Cardiovascular Convergence Research Center Nominated by Korea Ministry of Health and Welfare, Gwangju, Korea.
Chonnam Med J. 2018 Sep;54(3):167-172. doi: 10.4068/cmj.2018.54.3.167. Epub 2018 Sep 27.
We evaluated the effects of Ivabradine on left ventricle (LV) ejection fraction (EF) and LV infarcted tissue in the rat myocardial ischemia-reperfusion model. Twenty rats were randomly assigned to group 1 (ischemia-reperfusion, no treatment, n=10) and group 2 (ischemia-reperfusion + Ivabradine 10 mg/kg, n=10). Ivabradine was administered for 28 days. Echocardiography was performed at 7 days and at 28 days after the induction of ischemia-reperfusion injury. Cardiac fibrosis induced by ischemia-reperfusion injury was evaluated by Masson's trichrome staining. The infarct size was quantified using the Image J program. At the 28-day follow-up, LVEF was significantly higher (36.02±6.16% vs. 45.72±2.62%, p<0.001) and fractional shortening was significantly higher (15.23±2.84% vs. 20.13±1.38%, p<0.001) in group 2 than group 1. Delta (28 day minus 7 day) EF was significantly higher in group 2 than group 1 (-4.36±3.49% vs. 4.31±5.63%, p<0.001). Also, heart rate (beats/min) was significantly lower in group 2 than group 1 (251.67±25.19 vs. 199.29±31.33, p=0.025). Group 2 had a smaller infarct size (40.70±8.94% vs. 30.19±5.89%, p<0.01) than group 1 at 28-day follow-up. Oral administration of Ivabradine could improve LV systolic function and reduce infarcted tissue area in rat myocardial ischemia-reperfusion model.
我们在大鼠心肌缺血再灌注模型中评估了伊伐布雷定对左心室（LV）射血分数（EF）和LV梗死组织的影响。将20只大鼠随机分为第1组（缺血再灌注，未治疗，n = 10）和第2组（缺血再灌注 + 伊伐布雷定10 mg/kg，n = 10）。伊伐布雷定给药28天。在缺血再灌注损伤诱导后7天和28天进行超声心动图检查。采用Masson三色染色法评估缺血再灌注损伤诱导的心脏纤维化。使用Image J程序对梗死面积进行定量。在28天随访时，第2组的左心室射血分数显著高于第1组（36.02±6.16% 对 45.72±2.62%，p<0.001），缩短分数也显著高于第1组（15.23±2.84% 对 20.13±1.38%，p<0.001）。第2组的Δ（28天减去7天）射血分数显著高于第1组（-4.36±3.49% 对 4.31±5.63%，p<0.001）。此外，第2组的心率（次/分钟）显著低于第1组（251.67±25.19对199.29±31.33，p = 0.025）。在28天随访时，第2组的梗死面积小于第1组（40.70±8.94% 对 30.19±5.89%，p<0.01）。口服伊伐布雷定可改善大鼠心肌缺血再灌注模型的左心室收缩功能并减少梗死组织面积。
